Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Posted by rob on March 31, 2010 under Uncategorized | 
Comments are off for this article
 |
Related Articles |
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Leukemia. 2010 Mar;24(3):658-60
Authors: Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP
PMID: 20010623 [PubMed - indexed for MEDLINE]